iScribe, an artificial intelligence (AI) note-taking tool that converts patient conversations into clinical notes and referrer and patient letters, has gained 15-20% of the Australian ophthalmology market since its launch at the beginning of 2024, reported its parent company Akuru.
The digital scribe technology is one of several similar technologies targeting the health market, particularly GPs, since rapid advancements in AI, automatic speech recognition and natural language processing made the technology possible over the past five years. But iScribe is probably the only one designed by an ophthalmologist, said co-founder, Akuru’s chief technology officer and Australian ophthalmologist Dr Chandra Perera.










